Format

Send to

Choose Destination
Int J Urol. 2017 Mar;24(3):230-235. doi: 10.1111/iju.13274. Epub 2017 Jan 9.

Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.

Author information

1
Department of Urology, Wakayama Medical University, Wakayama, Japan.
2
Department of Clinical Laboratory Medicine, Wakayama Medical University, Wakayama, Japan.
3
Department of Urology, Kinan Hospital, Wakayama, Japan.

Abstract

OBJECTIVES:

To identify biomarkers predicting prognosis in bladder cancer patients undergoing the gemcitabine and cisplatin regimen.

METHODS:

We studied 52 patients with metastatic bladder cancer treated with the gemcitabine and cisplatin regimen by evaluating the relationship between the expression of two biomarkers, ribonucleotide reductase subunit M1 and excision repair cross complementing 1, by immunohistochemistry and clinical outcomes.

RESULTS:

The patients with low expression of ribonucleotide reductase subunit M1 showed a higher objective response rate by the gemcitabine and cisplatin regimen than those with high expression of ribonucleotide reductase subunit M1 (80.0% and 45.5%, respectively). No differences were observed according to the expression level of excision repair cross complementing 1. Low expression of ribonucleotide reductase subunit M1 significantly prolonged overall survival and progression-free survival compared with the high expression group. Low expression of excision repair cross complementing 1 tended to prolong overall survival and progression-free survival, but there were no significant differences (P = 0.07 and 0.10, respectively). Multivariate analysis showed that the expression of ribonucleotide reductase subunit M1 was the only independent prognostic factor (P = 0.012).

CONCLUSIONS:

The expressions of ribonucleotide reductase subunit M1 seem to be associated with clinical response and survival in patients with metastatic bladder cancer treated with gemcitabine and cisplatin-based chemotherapy.

KEYWORDS:

biomarker; bladder cancer; chemotherapy; excision repair cross complementing 1; ribonucleotide reductase subunit M1

PMID:
28066957
DOI:
10.1111/iju.13274
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center